Trialssemaglutidenovo nordiskobesityclinicaltrials.gov

Novo Nordisk completes semaglutide real-world experience study in six emerging markets

The sEMa-LIFE study, which began 28 August 2026, collected patient and physician accounts of semaglutide's effect on daily life in overweight and obesity.

By Priya Raman · Science Reporter

Sep 30 08:00 ETSource: ClinicalTrials.gov

The wire

01Registration record NCT07850765 lists sEMa-LIFE as completed, assessing semaglutide's impact on daily life from both participant and physician perspectives across six emerging markets.
02Sponsor-run experience studies shape how semaglutide is marketed and discussed outside the US and EU, where access and prescribing patterns differ.
03No results, enrolment figures or market names are posted in the registry entry, and the design is observational rather than comparative.

From the source

Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
NCT07850765 · N/A · COMPLETED · Sponsor: Novo Nordisk A/S · Conditions: Overweight, Obesity.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07850765